Robyn Domsic
Rheumatology · Pittsburgh, PANPI 1790887966
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $25,300 of the $27,793 with a category attached, or 91.0%. AstraZeneca accounts for 66.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $19,484 and has fallen 74.9% since, to $4,885 in 2025.
Across 25 payments — averaging $1111.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$18K
- Astrazeneca UK Limited$3K
- Boehringer Ingelheim$3K
- E.r. Squibb & Sons, L.L.C.$2K
- CSL Behring$1K
- Vertex$383
Across 31 payments — averaging $5220.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kadmon Corporation LLC$57K
- Cumberland Pharmaceuticals, Inc.$44K
- Pfizer$40K
- Sanofi US Services Inc.$20K
What the payments were for
- Consulting fees$25,30091%
- Speaking & faculty fees$6162%
- Travel & lodging$1,3765%
- Food & beverage$5012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $18,429 |
| Astrazeneca UK Limited | 12 | $3,443 |
| Boehringer Ingelheim | 4 | $2,596 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,593 |
| CSL Behring | 1 | $1,350 |
| Vertex | 1 | $383 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,793 in reported general payments places this provider in the 85th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Actemra ActpenTocilizumab | 56 | $271,914 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 22 | $229,777 |
| Mycophenolic AcidMycophenolate Sodium | 14 | $18,251 |
| Hydroxychloroquine Sulfate | 229 | $10,558 |
| Mycophenolate Mofetil | 86 | $8,059 |
| Cevimeline Hcl | 25 | $4,976 |
| Gabapentin | 114 | $1,455 |
| MethotrexateMethotrexate Sodium | 52 | $1,395 |
| Leflunomide | 17 | $1,293 |
| Pentoxifylline | 30 | $1,265 |
| Prednisone | 95 | $1,064 |
| Losartan Potassium | 62 | $1,058 |
| Dexlansoprazole DrDexlansoprazole | 12 | $987 |
| Famotidine | 88 | $953 |
| Fluoxetine Hcl | 58 | $891 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Pittsburgh
- Rohit AggarwalPittsburgh$810K
- Susan ManziPittsburgh$67K
- Michael LuckePittsburgh$51K
- Chester OddisPittsburgh$38K
- Daniella SchwartzPittsburgh$38K
- Lindsay LedwichPittsburgh$37K
- Ghassan AlayliPittsburgh$24K
- Tanmayee BichilePittsburgh$24K
- Alan EpsteinPhiladelphia$1.2M
- Lawrence LeventhalHuntingdon Valley$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.